Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study-Reference-Cited by-同舟云学术

Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study

Published:2022-12-01 Issue:4 Volume:35 Page:219-223
ISSN:2300-6676
Container-title:Current Issues in Pharmacy and Medical Sciences
language:en
Short-container-title:

Author:

Kunecki Marcin¹^ORCID,Oleksy Tomasz¹^ORCID,Nozynski Jerzy²^ORCID,Podolec Piotr³^ORCID,Biernat Jolanta¹^ORCID,Deja Marek Andrzej⁴^ORCID,Golba Krzysztof Stanislaw¹^ORCID,Plazak Wojciech⁵^ORCID

Affiliation:

1. Department of Electrocardiology and Heart Failure , Medical University of Silesia , Katowice , Poland

2. Department of Histology and Embryology , Medical University of Silesia , Katowice , Poland

3. Department of Cardiac and Vascular Diseases , John Paul II Hospital, Jagiellonian University Medical College , Kraków , Poland

4. Department of Cardiac Surgery , Medical University of Silesia , Katowice , Poland

5. Department of Cardiac and Vascular Diseases John Paul II Hospital , Jagiellonian University Medical College , Kraków , Poland

Abstract

Abstract The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized. Recent studies have shown that stimulation of opioid receptors may confer a cardioprotective effect against I/R injury. Levosimendan, the inodilator, is indicated for the short-term treatment of acutely decompensated heart failure. We tested the hypothesis that levosimendan may provide cardioprotection in the opioid-like mechanism in the human myocardium.

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology,Molecular Biology,General Medicine,Biochemistry

Link

https://www.sciendo.com/pdf/10.2478/cipms-2022-0038

Reference22 articles.

1. 1. Kunecki M, Oleksy T, Biernat J, Kukla P, Szwajkos K, Podolec P, Deja M, Gołba K, Płazak W. Ischemic conditioning of human heart muscle depends on opioid-receptor system. Folia Med Cracov. 2017;57(2):31-39.10.20418/jrcd.vol2no6.228

2. 2. Li PC, Yang YC, Hwang GY, Kao LS, Lin CY. Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9(2):e85909.10.1371/journal.pone.0085909391190024498266

3. 3. Sorsa T, Polleselo P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitizer with cardiac troponin c. Moll Cell Biochem. 2004;266:87-107.10.1023/B:MCBI.0000049141.37823.1915646030

4. 4. Haikala H, Polleselo P. Calcium sensitivity enhancers. IDrugs. 2000;3:1199-205.

5. 5. Kaheinen P, Polleselo P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367-74.10.1097/00005344-200104000-0000311300649